- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Orchid Pharma unit inks pact with UK entity for $800 mn loan
NEW DELHI: Orchid Pharma said its subsidiary has inked a pact with UK's Line Trust International to avail loan of up to USD 800 million (about Rs 5,300 crore) to explore new growth avenues.
Orchid Europe Ltd, UK, a wholly-owned subsidiary of the company has entered into a long-term financial arrangement to avail up to USD 800 million as loan with Line Trust International, Guernsey, UK, Orchid Pharma said in a filing to BSE.
"This funding will help the company explore new growth opportunities while enabling the current business achieve incremental value," it added.
Orchid Pharma, formerly known as Orchid Chemicals & Pharmaceuticals, has earlier announced that it is in talks with banks to convert its rupee debt into dollar-denominated one.
The company has a total debt of around Rs 3,100 crore.
Set up in 1992 as an export-oriented unit, Orchid Chemicals & Pharmaceuticals has presence across segments such as anti-infectives, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products.
Next Story